TY - JOUR KW - Balkan KW - Tuberculosis KW - leprosy AU - Niåu M AU - Olteanu M AU - Cãlãraæu C AU - Olteanu M AU - Vasiliu R AU - Streba C AU - Postolache P AU - Golli AL AU - Pop C AU - Nemeæ RM AB -

Cutaneous tuberculosis represents a small percent of total extrapulmonary

TB forms, caused mainly by Mycobacterium tuberculosis.

Skin tuberculosis can be also highly variable in its clinical

appearance, significance, and prognosis. The form of the disease

depends on the virulence of the strain, the immune status of the

host, the portal of entry, the mode of internal spread, and the

adequacy of initial treatment. Lesions in the skin often represent

hematogenously or lymphatically dispersed disease from internal

foci of infection. Scrofuloderma and lupus vulgaris are much more

common and are seen in patients who are less immunosuppressed

and tuberculosis verrucosa cutis is highly seen in

patients who are immunocompetent. Leprosy (also known as

Hansen’s Disease) is a chronic, infectious disease involving

primarily the nerves and secondary the skin, mucosa and the eyes

of infected individuals. Leprosy is caused by Mycobacterium

leprae. Although this disease is curable since 1948, according to

WHO in 2013 there were registered 213.000 new cases of leprosy.

Considering the results of skin tests (biopsies, and secretions

tests) leprosy can be classified as: paucibacillary - few or absent

bacilli (tuberculoid leprosy, and borderline tuberculoid leprosy)

and multibacillary - numerous bacilli (lepromatous leprosy,

borderline lepromatous leprosy and borderline leprosy). Corroborating

clinical data with specific laboratory tests and biopsies of

the affected skin and nerves we establish the diagnosis and form

of these diseases; the tuberculin test has as correspondent

lepromin test. The treatment of cutaneous tuberculosis in most

cases is the same as for pulmonary tuberculosis. Early treatment

for leprosy prevents disabilities and scaring.

 

 

 

BT - Archives of the Balkan Medical Union C1 -

 

 

 

IS - 1 J2 - Arch Balkan Med Un LA - eng, fre N2 -

Cutaneous tuberculosis represents a small percent of total extrapulmonary

TB forms, caused mainly by Mycobacterium tuberculosis.

Skin tuberculosis can be also highly variable in its clinical

appearance, significance, and prognosis. The form of the disease

depends on the virulence of the strain, the immune status of the

host, the portal of entry, the mode of internal spread, and the

adequacy of initial treatment. Lesions in the skin often represent

hematogenously or lymphatically dispersed disease from internal

foci of infection. Scrofuloderma and lupus vulgaris are much more

common and are seen in patients who are less immunosuppressed

and tuberculosis verrucosa cutis is highly seen in

patients who are immunocompetent. Leprosy (also known as

Hansen’s Disease) is a chronic, infectious disease involving

primarily the nerves and secondary the skin, mucosa and the eyes

of infected individuals. Leprosy is caused by Mycobacterium

leprae. Although this disease is curable since 1948, according to

WHO in 2013 there were registered 213.000 new cases of leprosy.

Considering the results of skin tests (biopsies, and secretions

tests) leprosy can be classified as: paucibacillary - few or absent

bacilli (tuberculoid leprosy, and borderline tuberculoid leprosy)

and multibacillary - numerous bacilli (lepromatous leprosy,

borderline lepromatous leprosy and borderline leprosy). Corroborating

clinical data with specific laboratory tests and biopsies of

the affected skin and nerves we establish the diagnosis and form

of these diseases; the tuberculin test has as correspondent

lepromin test. The treatment of cutaneous tuberculosis in most

cases is the same as for pulmonary tuberculosis. Early treatment

for leprosy prevents disabilities and scaring.

 

 

 

PY - 2015 SP - 105 EP - 110 T2 - Archives of the Balkan Medical Union TI - A Comparison Between Cutaneous Tuberculosis And Leprosy UR - http://see-articles.ceon.rs/data/pdf/0041-6940/2015/0041-69401501105N.pdf VL - 50 ER -